Lytix Biopharma AS (OSL:LYTIX)
Norway
· Delayed Price · Currency is NOK 10.20
0.00 (0.00%)
At close: Dec 5, 2025
Lytix Biopharma AS Income Statement
Financials in millions NOK. Fiscal year is January - December.
Millions NOK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
| Operating Revenue | 0.38 | 11.13 | 3.99 | 11.03 | 19.31 | 0 | Upgrade
|
| Other Revenue | - | - | - | - | - | 4.07 | Upgrade
|
| Revenue | 0.38 | 11.13 | 3.99 | 11.03 | 19.31 | 4.07 | Upgrade
|
| Revenue Growth (YoY) | -96.50% | 178.98% | -63.82% | -42.86% | 373.91% | -35.73% | Upgrade
|
| Gross Profit | 0.38 | 11.13 | 3.99 | 11.03 | 19.31 | 4.07 | Upgrade
|
| Selling, General & Admin | 30.49 | 22.63 | 24.37 | 20.41 | 31.1 | 24.81 | Upgrade
|
| Research & Development | 30.79 | 72.57 | 63.17 | 45.61 | 23.74 | 16.01 | Upgrade
|
| Other Operating Expenses | 13.61 | 10.92 | 12.28 | 9.76 | 12.01 | 5.63 | Upgrade
|
| Operating Expenses | 75.87 | 107.03 | 100.78 | 76.7 | 67.29 | 46.45 | Upgrade
|
| Operating Income | -75.49 | -95.9 | -96.79 | -65.67 | -47.99 | -42.37 | Upgrade
|
| Interest Expense | -0.23 | -0.13 | -0.06 | -0.15 | -0.07 | - | Upgrade
|
| Interest & Investment Income | 2.07 | 1.51 | 2.35 | 1.41 | 0.14 | 0.35 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.34 | -0.08 | 4.01 | 7.72 | -0.17 | -0.07 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.08 | 0.33 | 2.59 | 0.61 | 0.01 | 0.01 | Upgrade
|
| EBT Excluding Unusual Items | -73.23 | -94.27 | -87.9 | -56.07 | -48.08 | -42.09 | Upgrade
|
| Pretax Income | -73.23 | -94.27 | -87.9 | -56.07 | -48.08 | -42.09 | Upgrade
|
| Earnings From Continuing Operations | -73.23 | -94.27 | -87.9 | -56.07 | -48.08 | -42.09 | Upgrade
|
| Net Income | -73.23 | -94.27 | -87.9 | -56.07 | -48.08 | -42.09 | Upgrade
|
| Net Income to Common | -73.23 | -94.27 | -87.9 | -56.07 | -48.08 | -42.09 | Upgrade
|
| Shares Outstanding (Basic) | 68 | 54 | 40 | 40 | 33 | 26 | Upgrade
|
| Shares Outstanding (Diluted) | 68 | 54 | 40 | 40 | 33 | 26 | Upgrade
|
| Shares Change (YoY) | - | 35.05% | 1.01% | 19.50% | 26.57% | 14.56% | Upgrade
|
| EPS (Basic) | -1.07 | -1.74 | -2.19 | -1.41 | -1.45 | -1.60 | Upgrade
|
| EPS (Diluted) | -1.07 | -1.74 | -2.19 | -1.41 | -1.45 | -1.60 | Upgrade
|
| Free Cash Flow | -57.18 | -70.37 | -96.02 | -52.78 | -44.61 | -24.35 | Upgrade
|
| Free Cash Flow Per Share | -0.84 | -1.30 | -2.40 | -1.33 | -1.34 | -0.93 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -20023.87% | -861.29% | -2425.08% | -595.28% | -248.54% | -1040.06% | Upgrade
|
| Profit Margin | -19424.67% | -846.64% | -2202.38% | -508.29% | -249.02% | -1033.09% | Upgrade
|
| Free Cash Flow Margin | -15167.37% | -632.05% | -2405.86% | -478.47% | -231.04% | -597.62% | Upgrade
|
| EBITDA | -75.44 | -95.83 | -96.72 | -65.64 | -47.53 | - | Upgrade
|
| EBITDA Margin | - | - | - | - | -246.20% | - | Upgrade
|
| D&A For EBITDA | 0.05 | 0.07 | 0.06 | 0.03 | 0.45 | - | Upgrade
|
| EBIT | -75.49 | -95.9 | -96.79 | -65.67 | -47.99 | -42.37 | Upgrade
|
| EBIT Margin | - | - | - | - | -248.54% | - | Upgrade
|
| Revenue as Reported | 0.38 | 11.13 | 3.99 | 11.03 | 19.5 | 6.68 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.